Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06530290
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-04-22
Brief Title:
Evaluating the Effect of Mirtazapine on Anxiety in Parkinsons Disease Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluating the Effect of Mirtazapine on Anxiety in Parkinsons Disease Patients a Randomized Double-blinded Placebo-controlled Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center parallel and double-blind study in Movement Disorders Clinic of Shohadaye Tajrish Hospital Patients researchers physicians outcome assessors and data analysts are blinded After assessing the inclusion and exclusion criterias patients who assigned the informed consent form are randomly divided into control and treatment groupsPatients in treatment or placebo groups respectively receive mirtazapine 15 mg or placebo once a day for 12 weeks Primary anxiety and secondary depression fatigue sleep disorders and quality of life outcomes are evaluated at baseline and after 4 and 12 weeks of treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None